Author: Editor

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT). For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar looks at current statistics for methods of adding to targeted therapy, as well as giving an overview of biology in treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses what the patient can do to advocate for themselves during treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses treatment options for patients with locally advanced NSCLC, and how to proceed while waiting for trial data. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses considerations and questions for targeted therapy before surgery. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss explains why immunotherapy is not typically given to patients with resectable NSCLC and a driver mutation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as a treatment for EGFR+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai discusses the administration of therapy for biomarkers, and how to overcome the gaps in administration, access, and affordability. For more, please visit http://cancerGRACE.org/. To watch the complete video click here: https://www.youtube.com/watch?v=v85bJi-vtGM&t=3939s BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing. For more, please visit http://cancerGRACE.org/. To watch the full video click here: https://www.youtube.com/watch?v=ksZ6w3CEdPg BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

By. Nicolas Rigard, MDDate. 11/20/2023In this interview, Nicolas Girard, MD, a medical doctor and professor of respiratory medicine at Versailles, St. Quentin University, and the head of the Curie-Montsouris Thorax Institute, discusses the PAPILLON study. The interview, conducted by Alan from OncologyTube, explores the comparison between Amivantamab plus chemotherapy and chemotherapy alone as the first-line treatment for EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer.Nicolas Girard, MD, provides an overview of the study’s primary endpoint, progression-free survival (PFS), emphasizing the reduction in the risk of disease progression and the extension of median PFS with the Amivantamab plus chemotherapy combination.…

By. Kim Margolin, MDDate. 11/17/2023In the field of cancer immunotherapy, Kim Margolin, MD, provides insights into the interplay between the innate and adaptive immune systems. According to her, the innate immune system serves as a bridge, reacting swiftly against pathogens. This orchestration involves the secretion of cytokines, cytotoxic granules, and the engulfing of pathogens. Margolin emphasizes the concert between innate and adaptive immune responses, highlighting the significance of acute inflammation in anticancer reactions, in contrast to immunosuppression associated with chronic inflammation.Margolin delves into the field of tertiary lymphoid structures within tumors, elucidating their composition, which mirrors that of the adaptive…

By. Joaquim Bellmunt, MD, PhD Date. 11/17/2023 At the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, Dr. Joaquim Bellmunt, MD, PhD, from Harvard Medical School in Boston, MA, shared insights on advancements in renal cancer during a dedicated session. Discussing first-line treatment options, Dr. Bellmunt highlighted the four established choices, including combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors. In an interview, he touched upon the critical analysis of which patients are best suited for each treatment strategy. During the session, Dr. Bellmunt delved into the Phase III CONTACT-02 trial (NCT04446117) focusing on prostate…

By. Crispin Hiley, PhD Date. 11/17/2023 Crispin Hiley, PhD, from the UCL Cancer Institute in London, UK, discusses developments in second-line treatment for EGFR mutation-positive lung cancer patients at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. Crispin Hiley, PhD, acknowledges progress in addressing the needs of patients who have progressed on osimertinib or third-generation tyrosine kinase inhibitors (TKIs). In an interview, Crispin Hiley, PhD, talks about studies on second-line EGFR mutation-positive lung cancer and the challenges faced by patients advancing on tyrosine kinase inhibitors. He acknowledges the existing unmet need, especially for those not suitable…

By. Mansoor Raza Mizra, MD Date. 11/16/2023 At ESMO this year, Mansoor Raza Mizra, MD, a figure in gynecologic oncology, shared insights on developments in the field. The focus began with cervical cancer, where three phase three randomized trials showed results. The Interlace trial, conducted in the neoadjuvant setting for locally advanced cervical cancer, demonstrated outcomes in both progression-free survival (PFS) and overall survival (OS). Another trial, exploring Cho radiation with or without pisab concomitant and maintenance in locally advanced cervical cancer, showed an increase in PFS, with a trend in OS, though data maturity is awaited. The third trial,…

By. Nicolas Girard, MD Date: 11/15/2023 In a significant development in the field of oncology, Nicolas Girard, MD, played a role in the approval of Amivantamab for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions. The approval specifically targets individuals who have experienced disease progression during or after platinum-based chemotherapy, representing an advancement in therapeutic options. The approval stems from a phase 3 international randomized trial overseen by Dr. Nicolas Girard and colleagues. In this trial, 308 patients with advanced NSCLC and EGFR exon 20 insertions, previously untreated with…

By: Allison Betof Warner, MD, PhD, StanfordDate: 11/13/2023 From: MOASCImmuno-Oncology Determining Optimal Treatment Duration Transcript: The question of how long to treat patients is one of the more challenging ones in our field. It’s always wonderful when our patients are responding. Classically in oncology, we kept patients on treatment indefinitely in the days of chemotherapy and even targeted therapy. Um, but we really feel that the immune system can learn to take care of a cancer itself from immunotherapy. And all of the data have suggested that over the years. the question is, how do we pick which patient is…

By. Aaron E. Lisberg, MD, Date. 11/14/2023 During ESMO 2023, Aaron E. Lisberg, MD, delivered a presentation on the results from the TROPION-Lung01 study, focusing on the clinical question of second-line chemotherapy for advanced metastatic non-small cell lung cancer compared to docetaxel. The study investigated a novel antibody-drug conjugate targeting TROPION-Lung01, Datopotamab deruxtecan, in a head-to-head comparison with docetaxel. Approximately 300 patients were enrolled and randomized at a one-to-one ratio, regardless of histology or the presence of targetable mutations. The trial had dual primary endpoints—progression-free survival (PFS) and overall survival (OS). Dr. Lisberg’s presentation concentrated on the PFS final analysis…

By. Filippo Pietrantonio, MD Date: 11/14/2023 Clinical data from the study demonstrated the inhibition of feedback reactivation pathways with an accumulation of activated GFR, providing a compelling rationale for combining Sotorasib with an anti-EGFR monoclonal antibody. Dr. Pietrantonio, MD, emphasized the need to enhance outcomes beyond monotherapy. The CodeBreak 300 trial, a global and phase 3 active-controlled open-label study, involved 160 patients randomized based on centrally confirmed KRAS G12C mutations after the failure of standard therapies. The trial featured three arms: Sotorasib at the standard dose (960 mg) plus panitumumab, Sotorasib at a lower dose (240 mg) plus panitumumab, and…

By. Peter Schmid, FRCP, MD, PhD Date. 10/11/2023 KEYNOTE-522 Phase 3 Results – Was Pembrolizumab a Win in Triple-Negative Breast Cancer? In this interview, Peter Schmid, FRCP, MD, PhD, from Barts Cancer Institute, London, UK, delves into the compelling 5-year follow-up data emanating from the Phase III KEYNOTE-522 (NCT03036488) trial. The trial was designed to investigate the efficacy of combining pembrolizumab with chemotherapy as neoadjuvant therapy and pembrolizumab as adjuvant therapy in patients grappling with the challenges of triple-negative breast cancer. The previously reported findings from the trial had already indicated noteworthy and statistically significant improvements in both pathological complete…

By. Funda Meric-Bernstam, MD Date. 10/11/2023 LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients with HER2-expressing solid tumors. Professor Funda Meric-Bernstam presented pivotal findings at the ESMO Congress 2023, shedding light on the latest developments in the realm of cancer treatment. The focal point of her presentation was the noteworthy LBA34 – Trastuzumab deruxtecan (T-DXd) for HER2-expressing solid tumors. These insights emanated from the primary analysis of the DESTINY-PanTumor02 (DP-02) study, offering a comprehensive examination of T-DXd’s efficacy in a diverse cohort of patients. The study, designed to address the therapeutic potential of T-DXd, specifically targeted patients with HER2 expression…

By. Yennifer Chan, MD Lisa Yen, MD Courtesy: LACNETS Date. 11/09/2023 Cabozantinib in the CABINET Trial: NET Results Lisa Yen, MD, the Director of Programs and Outreach at ESMO 2023 in Madrid, is alongside Dr. Jennifer Chan, the Principal Investigator of the Alliance Phase Three Study. This study, known as the Cabinet Study, explores Cabozantinib’s efficacy compared to a placebo in Advanced Neuroendocrine Tumors after prior therapy. Dr. Chan recently revealed the trial’s outcomes, demonstrating the effectiveness of Cabozantinib in both cohorts of patients. The results showed an improvement in progression-free survival for those receiving Cabozantinib compared…

By: Dr. Rahul Gusain, MD Dr. Rohit Gusain, MD Dr. Joshua Reuss, MD Date: 11/07/2023 Courtesy: OncologyBrothers Drs. Rahul Gosain, MD and Rohit Gosain, MD, referred to as the oncology brothers, reflected on the impressive content presented at ESMO 2023. They segmented the lung cancer highlights into two key studies: KEYNOTE 671 focusing on resectable non-small cell lung cancer and the Alina trial for ALK-positive patients. They were joined by Dr. Joshua Reuss from Georgetown Lombardi Kansas Center. KEYNOTE 671 Results from ESMO 2023 KEYNOTE 671, a phase 3 study, examined the peroperative IO…

The full video from the Spanish Targeted Therapies in Lung Cancer Patient Forum 2023 is available now to view ONDemand, while we edit and produce smaller videos by topic. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai discusses the current recommendations for biomarker testing in patients with NSCLC, as well as best practices. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai gives a basic overview of biomarkers and discusses which ones are important for patients with NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai details the importance of biomarker testing and discusses the method of liquid biopsy to do so. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

This full unedited version of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday, July 15, 2023 is now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks. For the breakout presentations from the 2nd Stage, please see: https://youtu.be/XITX_YhElIE For more, please visit http://cancerGRACE.org/. To ask a question, visit https://cancergrace.org/forum.

This full unedited version of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday, July 15, 2023 is now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks. For the full mainstage presentations please see: https://youtu.be/v85bJi-vtGM For more, please visit http://cancerGRACE.org/. To ask a question, visit https://cancergrace.org/forum.

By: Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea, Date: 11/03/2023 Courtesy: VJOncology Above is a video from Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea about the MARIPOSA Phase 3 trial a randomized study comparing amivantamab plus lazertinib compared to osimertinib in advanced EGFR mutated lung cancer. During this ESMO 2023, the primary and some secondary endpoints of the MARIPOSA study were presented. The primary endpoint of the MARIPOSA study aimed to evaluate the progression-free survival (PFS) of amivantamab plus lazertinib compared to osimertinib according to RECIST version 1.1. The secondary endpoints included overall survival, duration of…

By. Stuart McIntosh, MDDate. November 03, 2023Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology. His work involved combining samuraciclib, a CDK7 inhibitor, with elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), specifically for patients with CDK4/6 inhibitor-resistant HR+, HER2- metastatic breast cancer.The study aimed to address resistance to CDK4/6 inhibitors in this specific patient subset. McIntosh’s research sought to explore the benefits of this combination therapy, focusing on efficacy, safety, and tolerability.The investigation explored the risks and benefits linked with the combination therapy. Early findings indicated potential therapeutic advantages in managing resistance in this…

By. Mohammed Dar, MDDate. November 02, 2023Mohammed Dar, MD, observed significant advancements in the treatment of metastatic uveal melanoma, particularly for HLA-A02:01 positive patients with the introduction of tebentafusp (TA BENT A FUSP). In comparison to the control group, tebentafusp demonstrated notable improvements in overall survival rates. The specific data revealed a substantial increase in survival rates among patients receiving tebentafusp compared to those in the control group. This has a significant impact on the current standard of care for HLA-A02:01 positive patients, potentially reshaping treatment protocols for this subgroup.Regarding early survival benefits, the first six weeks of tebentafusp treatment…

By. Corina Dutcus, MDDate. November 02, 2023Corina Dutcus, MD, a lead investigator in the Phase 3 LEAP-014 trial for metastatic esophageal squamous cell carcinoma, presented insights into the trial’s objectives, findings, and implications for patient care.The Phase 3 LEAP-014 trial aimed to evaluate the efficacy and safety of combining lenvatinib, pembrolizumab, and chemotherapy for this cancer type, focusing on overall survival, progression-free survival, and safety measures.Dr. Dutcus summarized the trial findings, noting improvements in overall survival, progression-free survival, and a manageable safety profile for the combination therapy.The addition of lenvatinib and pembrolizumab to chemotherapy represents a significant advancement in the…

By. Tyler Ames, PhDDate. November 01, 2023Tyler Ames, Ph.D. in oncology research, delves into the intricate mechanisms of PT-112’s impact on cancer cells and its potential significance in treating metastatic castration-resistant prostate cancer and thoracic malignancies.Addressing the significance of PT-112’s ability to release damage-associated molecular patterns (DAMPs) and induce immunogenic cell death (ICD), Dr. Ames underscores their pivotal role in the immune system’s response against cancer. The release of DAMPs triggers an immune response, alerting the body to recognize and target cancerous cells, particularly crucial in metastatic and castration-resistant prostate cancer and thoracic malignancies.When exploring the early molecular effects of…

By. Aditya Bardia, MDDate. November 01, 2023 Dr. Aditya Bardia, an oncologist specializing in breast cancer treatment, provided insights into the NATALEE trial, presenting pivotal data at ESMO 2023. The trial, under his leadership, aimed to advance breast cancer therapy and contribute significantly to understanding treatment modalities. Dr. Bardia’s contributions to the trial and subsequent findings established him as a prominent figure in advancing breast cancer research. The NATALEE trial had specific objectives, focusing on improving outcomes for patients with HER2-positive early breast cancer. It investigated the effectiveness of dual HER2 blockade (using two anti-HER2 agents) in combination with chemotherapy…

By. Corina Dutcus, MDDate. November 01, 2023Corina Ductus, MD, a medical doctor and the Senior Vice President of Clinical Development at Eisai, recently addressed critical aspects of the Phase 3 Study 309/KEYNOTE-775 trial focusing on patients with advanced endometrial cancer. The trial specifically evaluated the efficacy of pembrolizumab in combination with lenvatinib for patients who had undergone prior platinum therapy.During the interview, Dr. Ductus discussed the key findings from the trial. The research showcased significant improvements in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). These statistically and clinically significant enhancements in patient outcomes hold immense significance…

Author: Dr Antonio Passaro (on-camera comments) – Courtesy of ESMO.org At the ESMO 2023 conference, the results of the Phase three global randomized Mariposa 2 trial were presented. The trial focused on patients with advanced non-small cell lung cancer after progressing on Ozimertinib due to an EGFR mutation. The study aimed to evaluate Amivantamab combined with chemotherapy, with or without Lazertinib, compared to standard chemotherapy. The trial involved 657 patients from various regions and aimed to assess progression-free survival. The primary endpoint was to compare the survival benefits among the different treatment arms. The study found a statistically significant improvement in…

Author: Dr. Yelena Janjigian (on-camera comments) – Courtesy of ESMO.org The Matterhorn study, a significant phase three global research effort, aims to determine the efficacy of a triplet regimen involving chemotherapy with flood alongside durvalumab in treating early-stage non-metastatic gastric and gastroesophageal adenocarcinoma. Presented at ESMO 2023, the study’s first interim analysis involved nearly 1000 patients from various regions globally, utilizing a randomized approach of flood plus durvalumab or placebo. Results revealed a 12% enhancement in complete response rate and a 15% improvement in node negativity status, which is crucial for clinical outcomes. While the study successfully met its interim…

By. Antonio Passaro, MDDate. October 31, 2023Antonio Passaro, MD, an oncologist specializing in lung cancer, has been deeply involved in the analysis and interpretation of the Phase 3 MARIPOSA-2 study. The primary objective of this pivotal trial was to investigate the efficacy and safety of the amivantamab regimen, in combination with chemotherapy, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations.The study’s key findings have been groundbreaking, revealing a significant advancement in the treatment landscape for NSCLC. Dr. Passaro highlights the remarkable results that demonstrate a 56% and 52% reduction in the risk…

By. Noura Choudhury, MD Date. October 31, 2023Noura Choudhury, MD, a medical researcher specializing in oncology therapeutics, is a key figure in understanding the clinical significance of HPN328, a cutting-edge immunotherapy drug. Her expertise and experience in the field enable a comprehensive analysis of recent clinical trial data and its implications for cancer treatment.In the interview, Dr. Noura Choudhury addresses the significant insights drawn from HPN328’s clinical trial results. Highlighting the drug’s remarkable confirmed response rate of 35% across diverse tumor types with a mere 1 mg priming dose, including instances of complete responses, she elucidates the potential implications for…

By. Mohamed H. Derbala, MDDate. October 31, 2023Mohamed H. Derbala, MD, an immuno-oncology expert and a Research Scientist at MD Anderson Cancer Center, is slated to share his expertise during an exclusive interview. The discussion will revolve around pivotal inquiries concerning TIGIT and its implications in immunotherapy.The interview will provide a comprehensive exploration of various critical facets related to TIGIT. Dr. Derbala will delve into the intricate role that TIGIT plays in immune suppression, shedding light on its function as an inhibitory receptor impacting immune cells such as T cells and natural killer (NK) cells. His extensive research and findings…

By. Corina Dutcus, MDDate. October 30, 2023In this video interview, Corina Dutcus, MD, will address pivotal aspects of phase 3 CLEAR study, focusing on the combination of lenvatinib and pembrolizumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC). She will dive into the key findings and their implications for clinical practice.Dr. Dutcus will highlight the study’s pivotal results, emphasizing the better objective response rate (ORR) achieved with the lenvatinib and pembrolizumab combination compared to sunitinib. She will explain the significance of ORR in this context, elucidating its role as a metric in evaluating treatment efficacy.Furthermore, the discussion…

Author: Dr Michiel van der Heijden (on-camera comments) – Courtesy of ESMO.org Checkmate 901, a study focusing on first-line treatment for metastatic or irresectable urothelial cancer patients, aimed to improve existing chemotherapy approaches. Traditionally, chemotherapy, primarily cisplatin or gemcitabine, has been the standard for such cases. With the recent introduction of immunotherapy, there has been a challenge as many patients were unable to transition to immunotherapy post-chemotherapy. Involving around 600 patients, the study randomized participants into two groups: one receiving the standard cisplatin-gemcitabine and the other receiving this combination along with nivolumab, a checkpoint inhibitor. The trial successfully met its…

Dr Laurence Albiges (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, an individual presented a study at the forefront of oncology research. The study, known as LITESPARK-005, focused on patients with advanced kidney cancer who had previously undergone unsuccessful therapy. The trial explored the effectiveness of Belzutifan, a first-in-class inhibitor, in treating clear cell renal cell carcinoma (RCC) by targeting the hypoxia-inducible factor. This inhibitor, Belzutifan, works by impeding the dimerization of IF 2A, thereby blocking the downstream oncogenic pathway. The study enrolled over 700 patients and demonstrated positive outcomes. Primary results showed a significant increase in progression-free survival…

Author: Dr Herbert Ho Fung Loong (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, I’ve had the pleasure of presenting our groups data which is the Libretto 431 study which is actually a first line study of the use of supper catching it versus standard chemotherapy plus pembrolizumab in patients with newly diagnosed red fusion positive non small cell lung cancer. So by way of background red fusion accounts for about 2% of all non small cell lung cancers. And previously at least prior to the knowledge of knowing the fact that RET as a driver for most of these…